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ADENOVIRUS INFECTION (AI) AND DISEASE (AD) IN PEDIATRIC 
MATCHED UNRELATED DONOR BONE MARROW TRANSPLANT (BMT) 
PATIENTS RECEIVING EITHER ANTI-THYMOCYTE GLOBULIN (ATG) 
OR CAMPATH DURING CONDITIONING 
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Recent reports have shown an increased incidence of AI in 
patients treated with Campath. The incidence of AI/AD was 
compared in 112 patients at our institution who underwent allo- 
geneic BMT receiving either ATG or Campath during condition- 
ing. AI was defined as isolation of adenovirus in culture or detec- 
tion by PCR from a single site. AD was defined as 
isolation/detection in blood or end organ involvement. Two 
patients with AI were excluded for receiving both medications. AI
was present in 25% overall (27/I10), AD was seen in 1.8% 
(2/i10). Of those receiving ATG (72/110), AI rate was 24% 
(17/72) and AD was in 1.4% (l/72); for those receiving Campath 
(43/112) AI rate was 28% (13/43) and AD was in 2.3% (1/43) 
(p=0.69). Mortality for the entire group was 30% (34/112). Two 
of the 27 patients with AI died of AD. One patient received Cam- 
path and had grade 1V graft versus host disease (GVH). The sec- 
ond patient received ATG and had no GVH. These findings ug- 
gest no difference in adenovirus associated infection and disease 
rates among those receiving conditioning containing either ATG 
or Campath. Several risk factors have been identified for AD in 
the BMT patient including prolonged CD4 suppression, grade II- 
IV GVH and viral isolation from multiple sites. We plan to fur- 
ther delineate risk factors by measuring viral load by real time 
PCR and monitoring adenovirus pecific immune response by 
Elispot. 
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DETECTION OF PEPTIDE-SPECIFIC ALLOREACTIVE T CELLS USING 
HLA CLASS I TETRAMERS 
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After stem cell or solid organ transplantation alloreactive T cells 
are stimulated and form a vigorous response to allogeneic HLA 
molecules. In the absence of aggressive imrnunosuppression 
strategies these cells cause graft versus host disease and graft rejec- 
tion. We sought o obtain evidence that the magnitude of the T 
ceil alloresponse results from the numerous potential antigenic 
targets created by the diverse range of peptides presented by allo- 
geneic HLA molecules. HLA tetrameric complexes were used to 
identify the ligands recognised by alloreactive T cells. A panel of 
A*0201/peptide t trameric complexes was generated representing 
abundant self peptides known to bind endogenously to 3.*'020I. 
Alloreactive CDS+ T cell lines specific for A*0201 were stimulated 
in vitro and screened for tetramer binding by flow cytomerry to 
identify and quantify cells that recognise ach HLA/peptide 
alloantigen. For all HLA/peptide combinations tested a small 
population of tetranaer binding CD8+ T ceils was found. 
Tetramer-binding T cells exhibited exquisite specificity for the 
peptide bound by allogeneic A*0201 and peptide specific alloreac- 
tire T cells could be induced by both disparate and veW limited 
HLA mismatches. These alloreactive T cells were shown to origi- 
nate from the memory T cell population indicating that they rep- 
resent cross reactive T cells previously stimulated by antigenic 
peptides from foreign pathogens presented by self MHC mole- 
cules. TNF c~ expression along with enhanced expression of per- 
forin and IFN 7 was detected in tetramer binding cells demon- 
strating that the peptide alloreactive T cells are functional. Our 
results provide evidence to support he theory that the vigorous 
alloreactive T cell response is caused by the summation f numer- 
ous responses to each of the peptides bound by the allogeneic 
HLA molecules and show that tetramers can be used to detect 
functional alloreactive T cells. The panel of tetramers i currently 
being used to screen for alloreactive T cells in HLA mismatched 
transplant patients. 
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SELECTIVELY DEPLETING HOST-REACTIVE T CELLS FROM PERIPH- 
ERAL BLOOD STEM CELL ALLOGRAFTS - PRELIMINARY RESULTS OF 
A FEASIBILITY STUDY 
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Ex vivo selective depletion (SD) is a strategy to prevent graft- 
versus-host-disease (GVHD), in which host-reactive donor lym- 
phocytes are selectively eliminated from a peripheral blood stem 
cell (PBSC) allograft while conserving useful donor immune func- 
tion. We initiated a clinical study to assess the feasibility of this 
approach in the setting of nonmyeloablative st m cell transplants 
(NST) in older patients with hematologic malignancies. Three 
patients (median age 66 years) with advanced myelodysplastic syn- 
drome (2 RAEB, 1 RAEB-AML) received alow intensity prepara- 
tive regimen consisting of cyclophosphamide and fludarabine, fol- 
lowed by a "selectively-depleted" PBSC allograft from an 
HLA-identical sibling donor. To obtain such a graft, a 
positive/negative s lection (Isolex 300i) was performed on G- 
CSF-mobilized onor peripheral blood to generate a stein celI- 
rich product containing a CD34+ cell dose of >3xl06/kg and a 
CD3+ cell dose of 5xl04/kg. The remaining fraction was then co- 
cultured with irradiated lymphocytes obtained from the patient 
before transplant by apheresis. After 72 hours an anti-CD25 
imnmnoto.'dn, RFI'5-SMPT-dgA, was added to remove alloreact- 
ing cells. The washed T cell product (CD3+ cell dose of 1-2 x 
10e/kg) was infused following the preparative regimen, together 
with the stem cell-rich product. All patients received post-trans- 
plant immunosuppression with cyclosporine for a minimum of 30 
days, followed by dose reduction depending on the degree of 
donor lymphocyte chimerism. SD lymphocytes were successfully 
generated for all patients, meeting release criteria for cell num- 
bers, viability, and sterility and were infused safely without any 
untoward effects. All patients achieved 100% donor T cell 
engraftment by day 30, comparable to that seen with unmanipu- 
fated NST. Rapidly-resolving rades I and II skin-GVHD 
occurred in two patients, and no patient died of transplant-related 
causes. This is in contrast o a 35% TRM seen in a previous 
cohort of older patients receiving the same protocol without SD. 
Two survive 43-365 days post transplant, one patient (with AML 
at time of transplant) died day 200 of progressive l ukemia. These 
preliminary results are promising and demonstrate he ability of 
SD lymphocytes to engraft. 
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ANTI-LEUKEMIC ACTIVITY OF CHRONIC GRAFT-VERSUS-HOST DIS- 
EASE FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION 
IN ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE 
ACUTE LYMPHOBLASTIC LEUKEMIA 
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The aim of this study was to evaluate the outcomes for Philadel- 
phia chromosome-positive acute lymphoblastic leukemia (Ph+ 
ALL) in remission treated with allogeneic bone marrow rransplan 
tation (BMT). Twenty-three adults were entered onto this study. 
The 2-year probabilities of relapse and disease-fi'ee survival (DFS) 
were 39.4% and 43.5%, respectively. The presence of chronic 
graft-versus-host disease (GVHD) was found to be an independ- 
ent predictive factor affecting lower relapse and DFS. To monitor 
the BCR-ABL transcript, we also analyzed 48 bone marrow sam- 
pies of 8 patients using real-time quantitative r verse transcrip- 
tion-polymerase chain reaction (RT-PCR). The kinetics of the 
normalized amount of BCR-ABL transcript (BCR-ABL/ABL) 
were well correlated with their clinical courses. In 6 patients with 
continuous remission after BMT, a rapid decrease in BCR-ABL 
amount o the PCR negative status after the development of 
chronic GVHD was observed. Meanwhile, routine bone marrow 
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